Future Webinars

Presenter: Adam Seegmiller, MD, PhD, Vanderbilt University Medical Center, Nashville, TN

Host: Annette S Kim, MD, PhD, Vanderbilt University Medical Center, Nashville, TN

Certificate of Attendance (PPT)

Handout (PDF)

Description:

Neoplastic hematology is at the forefront of personalized cancer medicine. Consequently, there has been a rapid expansion in the number of ancillary cytogenetic and molecular tests available for the analysis of these diseases. However, development of testing standards and decision support tools to help clinicians choose and interpret these tests have not kept pace. This results in inefficiency, excessive test ordering, and increased costs. The Diagnostic Management Team (DMT) is a multi-disciplinary group at Vanderbilt University Medical Center that responded to these challenges by developing evidence-based standards, updated workflows, and novel informatics tools to ensure that the right tests are ordered on the right patient at the right time and to assist with interpretation of complex results. Implementation of the DMT process has decreased unnecessary tests and test omissions, has increased the frequency of positive results, and has decreased test costs to patients and payers. This webinar will describe the DMT concept and demonstrate how implementation of DMT processes has led to these positive outcomes.

Learning Objectives:

1. Outline the need for new approaches to the application of molecular genetic testing to complex diseases.

2. Describe the concept of a diagnostic management team, its approach to complex testing processes, and its implementation in laboratory and clinical workflow.

3. Demonstrate the outcomes of diagnostic management team implementation on testing efficiency, effectiveness, and cost.

Level of Instruction: Intermediate

Contact Hours: 1.0

Lung Biomarker Guidleine presented by CAP, IASLC and AMP - Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors-

April 24, 2013

Certificate of Attendance (PPT)

Handout (PDF)

Presented by Lead Authors: Philip T Cagle MD FCAP; Marc Ladanyi MD; and Neal I Lindeman MD

Hosted by: Laura J Tafe, MD, Dartmouth-Hitchcock Medical Center

Download the Guideline at abstract

Download the Press Release

Description: The Lead Authors will present an overview of the guideline including its implementation and potential impact on future treatment guidelines.

Level of Instruction: Intermediate

Review of the Gene Patent Supreme Court Case

Friday, April 19, 2013

Certificate of Attendance (PPT)

Handout (PDF)

Presenter: Sandra S Park, Senior Attorney, ACLU

AMP Hosts: Roger Klein, MD, JD, Chair, Professional Relations Committee
and Ted Schutzbank, PhD, Chair, Training & Education Committee

Read the April 15th
Oral Arguments

Description:

On May 12, 2009, the ACLU and the Public Patent Foundation filed a lawsuit on behalf of AMP and other organizational and individual plaintiffs that sought to invalidate key claims of patents on two human genes, BRCA1 and BRCA2 that are associated with a heritable predisposition to breast and ovarian cancer. The case was ultimately accepted by the United States Supreme Court, with oral arguments taking place on Monday April 15, 2013.

Learning Objectives:

• Explain the medical and legal issues under consideration in the gene patent case and their significance.
• Distinguish the arguments of the petitioners (AMP et al.) and the respondent (Myriad) for and against the patent eligibility of human genes.
• Formulate your own opinion on the desirability gene patenting.
  
  

Level of Instruction: Beginner to Intermediate

Contact Hours: 1.0